Labcorp expands access to comprehensive genomic testing through new lung cancer program

Burlington, n.c.--(business wire)--labcorp (nyse: lh), a leading global life sciences company, understands the important and growing role of precision medicine and is working to ensure more people have access to targeted and personalized treatments. as part of this effort, the company is announcing a new sponsored testing program aimed at helping advanced non-small cell lung (nsclc) cancer patients and their physicians make informed treatment and care management decisions through comprehensive
LH Ratings Summary
LH Quant Ranking